INTRODUCTION
Statins are oral inhibitors of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, which are widely prescribed for their cholesterol-lowering properties. HMG-CoA reductase is the rate-limiting enzyme that catalyzes the conversion of HMG-CoA to L-mevalonate, a key intermediate for cholesterol biosynthesis 1 (FIG. 1) . Because statins were first approved for treatment of hypercholesterolemia 20 years ago, these drugs have established themselves as very well-tolerated agents with rare side effects. More recent studies (primarily in animal models of autoimmune diseases) have revealed that besides their lipid-lowering properties, statins exert pleiotropic immunomodulatory effects that may benefit treatment of neuro-inflammatory disorders, such as multiple sclerosis (MS). Statins are particularly attractive agents for the treatment of MS, as all currently approved therapies of the Food and Drug Administration, such as interferon-beta, glatiramer acetate (GA), mitoxantrone, and natalizumab, which are only partially effective, administered parenterally, and have side effects.
Immunomodulatory mechanism of action
Besides cholesterol reduction, HMG-CoA reductase regulates the production of isoprenoid intermediates in the branched mevalonate pathway. 2 (FIG. 1) . Numerous studies have investigated the role of these isoprenoids in inflammation associated with atherosclerosis and immune-mediated inflammatory conditions. The 15-carbon farnesyl pyrophosphate and the 20-carbon geranylgeranyl pyrophosphate participate in the post-translational modification of small regulatory proteins, a process known as isoprenylation. 3 Isoprenylation of these proteins is necessary for their intracellular trafficking and anchoring at the cytoplasmic surface of the plasma membrane, where they function. Among proteins that undergo isoprenylation are members of the Ras family, Rho/Rac/ cell division cycle 42 (cdc42) and Rab families. These small proteins act as molecular switches, cycling between inactive GDP-bound and GTP-bound active states, where they control various signaling pathways. 4 Ras proteins are farnesylated and primarily exert effects on cell differentiation and proliferation. Rho family proteins, which are geranylgeranylated, regulate cytoskeletal reor-ganization. Furthermore, prenylation is required for members of the Rab family of GTP binding proteins, which are geranylgeranylated and involved in vesicular membrane trafficking. Thus, by inhibiting HMG-CoA reductase, statins not only inhibit the synthesis of cholesterol, but also limit availability of isoprenoid intermediates, which are required for activation of various cell types, including immune cells.
Statins in treatment of experimental CNS autoimmunity
Experimental autoimmune encephalomyelitis (EAE), a murine model for MS, is characterized by relapsing or chronic paralysis. In EAE, myelin-specific CD4ϩ T cells cause CNS inflammation 5 which is associated with both demyelination and axonal damage. 6 Daily statin treatment could not only prevent the onset of EAE, 7-10 but also reverse clinical symptoms when treatment was initiated after paralysis was fully established. 7, 8 These studies demonstrated that statins interfere with the pathogenesis of EAE at various steps, including antigen presentation, activation and differentiation of myelinreactive T cells, and recruitment of leukocytes into the CNS. These pleiotropic statin effects on immune cell function and migration are discussed in the following sections.
Modulation of antigen presentation
Activation of CD4 ϩ T cells requires recognition of linear peptide antigens presented that are in the context of the major histocompatibility complex (MHC) class II molecules expressed on the surface of antigen presenting cells (APC).
Kwak and colleagues 11 demonstrated that atorvastatin inhibits upregulation of interferon (IFN)-␥-inducible MHC class II expression on endothelial cells as well as on monocytes. A later study reported an inhibitory effect of atorvastatin on IFN-␥-inducible MHC class II expression, including microglia, a residential APC population that may have a key role in antigen presentation within the CNS. 7 Inhibition of MHC class II upregulation on microglia by atorvastatin appeared to be mediated through inhibition of the mevalonate pathway as it was reversed by addition of mevalonate. Similarly, inhibition of MHC class II expression in human endothelial cells by simvastatin was reversed by mevalonate and the 20-carbon geranylgeranyl pyrophosphate, but not by squalene, indicating an involvement of GTP-binding proteins in MHC class II inhibition. 12 In addition to binding of the T-cell receptor to antigen presented in the context of the MHC class II molecule (signal 1), a second signal is required for efficient T-cell activation.
13 CD40 ligand, expressed on antigen-activated T cells express recognizes CD40 on the surface of APC. This interaction triggers expression of further co-stimulatory molecules on APC, such as B7-1 (CD80) and B7-2 (CD86), which subsequently interact with co-stimulatory molecules, such as CD28 on the surface of T cells (FIG. 2) . In vitro, simvastatin and atorvastatin both prevented maturation of professional APC, which resulted in a strongly reduced ability to mediate T-cell proliferation.
14 Activation of T cells could be restored by addition of either mevalonate or the 20-carbon geranylgeranyl pyrophosphate indicating that statins mediated inhibition of APC maturation through their effect on the mevalonate pathway. Similarly, atorvastatin inhibited IFN-␥-inducible expression of CD40, CD80, and CD86 molecules on microglial cells. 7 In addition, atorvastatin treatment was found to reduce secretion of APCderived cytokines that are involved in the differentiation of T cells into pro-inflammatory Th1 cells. 15 Taken together, these data suggest that statins inhibit various aspects of APC-T cell interaction required for pro-inflammatory T-cell activation (FIG. 2) .
Modulation of T-lymphocyte proliferation and differentiation
Independent of their effect on antigen presentation, statins may exert a direct inhibitory effect on T-cell proliferation as in vitro treatment of purified T cells could also inhibit proliferation when antigen was presented by untreated APC. 7 Aktas and colleagues 8 reported that this inhibitory effect on T-cell proliferation may be mediated through negative regulation of cellcycle progression consistent with inhibition of GTPasemediated cell proliferation. Subsequently, the same group demonstrated that atorvastatin-mediated phosphorylation of extracellular signal-regulated kinase 1 (ERK1) is responsible for T-cell anergy. ϩ T cells. They also exert an inhibitory effect on cell cycle progression, which directly inhibits T-cell proliferation. When activated, T-cell differentiation is deviated toward an anti-inflammatory Th2 phenotype. (APC ϭ antigen presenting cells; GATA3 ϭ GATA-binding protein 3; NF-B ϭ nuclear factor-B.)
CD4
ϩ T cells can be categorized based on the profile of cytokines that they secrete. 17 Th1 cells have an important role in initiating EAE, providing pro-inflammatory cytokines such as IFN-␥, interleukin (IL)-2 and IL-12, and tumor necrosis factor. Another subset of proinflammatory T cells, IL-17-secreting Th17 cells was discovered and identified to have a key role in sustaining inflammation and tissue damage in CNS autoimmunity. 18, 19 In contrast, Th2 cells that secrete IL-4, IL-5, IL-10, and IL-13, have downregulatory properties on the inflammatory cascade in EAE, and are believed to have a beneficial role in regulation of MS. Similarly, CD4ϩCD25ϩFoxP3ϩ regulatory T cells (Treg) may have a role in maintaining tolerance and preventing autoimmune disease and were recently described to be deficient in number and function in MS. 20 Several EAE studies indicate that statins suppress differentiation of myelin-specific CD4 ϩ T cells into proinflammatory Th1 cells and may promote Th2 differentiation. Statin treatment was associated with reduced phosphorylation (activation) of STAT4 (signal transducer and activator of transcription 4), which is required for IL-12-dependent Th1-differentiation and increased phosphorylation of STAT6, which is responsible for IL-4-dependent Th2 differentiation. 7 Nath and colleagues 21 demonstrated that in vitro statins promoted T-cell expression of GATA-binding protein 3 (GATA3), a transcription factor associated with Th2 differentiation. In this report, statin treatment also exerted an inhibitory effect on the activation of nuclear factor-B (NF-B) and T-bet, a T-box transcription factor associated with Th1 differentiation. [22] [23] [24] Whereas suppression of pro-inflammatory Th1 responses is the most consistent finding throughout these animal studies, not all investigations have demonstrated a corresponding induction of Th2 cytokines. For example, lovastatin was found to ameliorate experimental autoimmune uveitis, another Th-1 mediated autoimmune disease model, which was associated with an inhibition of pro-inflammatory cytokines without a corresponding induction of a Th2 cytokine profile. 25 Similarly, in collagen-induced arthritis, high-dose simvastatin suppressed collagen-specific Th1 humoral and cellular immune responses without an upregulation of Th2 cytokines. 26 These varying findings on the induction of Th2 cytokines under statin treatment may relate to differences in the model system, the statin used, and the dose. Alternatively, statin-mediated Th2 deviation might not be an active induction of anti-inflammatory Th2 cells, but rather an occurrence as a consequence of Th1 suppression. Whether statin treatment inhibits differentiation of pro-inflammatory Th17 cells and/or promotes development of Treg has not yet been reported.
Modulation of adhesion molecule expression on leukocytes and endothelial
Recruitment of leukocytes into the CNS occurs in a cascade of events, including chemoattraction, cell adhesion, extravasation, and proteolytic degradation of the extracellular matrix. The expression of adhesion molecules on both leukocytes and the endothelium plays an important role in the initiation of transmigration. The integrin leukocyte function antigen 1 is an adhesion molecule on lymphocytes that binds to intercellular adhesion molecule 1 (ICAM-1) expressed on the endothelium. Interestingly, both molecules have been identified to be expressed on infiltrating lymphocytes and endothelial cells in perivascular MS lesions. 27 Some data suggest that lovastatin can bind directly to the extracellular domain of leukocyte function antigen 1 independent of inhibition of HMG-CoA reductase, which results in a reduced adhesion capacity of lymphocytes to ICAM-1. 28 Correspondingly, macrophage adhesion molecule-1 (Mac-1) (CD11b/CD18) is the integrin expressed on monocytes binding to ICAM-1 on endothelial cells. In vitro, lovastatin was also shown to inhibit monocyte expression of Mac-1 and subsequent binding of these cells to the endothelium. 29 On endothelial cells, statins were shown to decrease both constitutive and induced expression of ICAM-1, the key molecule for leukocyte adhesion. 30, 31 Furthermore, lovastatin was recently reported to inhibit expression of vascular cell adhesion molecule-1, another adhesion molecule expressed on endothelial cells, resulting in a significantly reduced transendothelial cell migration. 32 Thus, statins inhibit recruitment of leukocytes into the CNS by suppressing expression of adhesion molecules on both activated leukocytes and brain endothelial cells. 33 
Inhibition of leukocyte migration and motility
Independent of its role as an adhesion molecule, ICAM-1 engagement results in intracellular signaling responses that facilitate lymphocyte transendothelial migration. 34 -37 In this regard, it was shown that in vitro treatment of brain endothelial cells with lovastatin inhibited transendothelial T-cell migration 10 consistent with the finding that Rho-GTPase is critically involved in transduction of ICAM-1-mediated signaling responses in brain endothelial cells, and consequently transendothelial migration of T lymphocytes. 34, 38 Once leukocytes crossed the endothelial barriers, they still have to traverse the basement membrane (basal lamina) of brain venuoles to access the CNS parenchyma. Due to their proteolytic properties, matrix metalloproteinases (MMPs) are physiologic mediators of cell migration through basement membranes and extracellular matrix. 39 Two reports demonstrated that statins reduced secretion of MMP-9 by monocytes in a dose-dependent manner, which was reversed by the simultaneous addition of exogenous mevalonate. 40, 41 Specifically, secretion of MMP-9 from the monocytic cell line THP-1 could be inhibited by an inhibitor selective for geranylgeranyl transferase pointing to Rho being involved in the inhibitory process. 42 Inhibition of monocyte MMP-9 secretion by cerivastatin in contrary was reversible by farnesyl pyrophosphate (FPP), thus implicating a role for Ras. 40 These data show that multiple small GTPase signaling pathways may be involved in MMP-9 production and as such may represent the mechanism by which statins inhibit their secretion.
Statins may be a treatment option for multiple sclerosis
The immunomodulatory effects of statins observed in animal models of inflammatory diseases provided the impetus for several clinical trials. In a first small openlabel study, seven relapsing-remitting MS patients with an active disease course received 20 mg lovastatin per day. 43 A brain MRI revealed decreased inflammation under lovastatin treatment, although no significant clinical changes were observed in this small cohort. In another small open-label trial, simvastatin was tested in patients with clinically definite relapsing-remitting MS. 44 Patients with at least one gadolinium-enhancing CNS lesion in the 3-month pre-treatment period were treated with 80 mg simvastatin daily for 6 months. Posttreatment MRI indicated a decrease of approximately 45% in the mean number and volume of gadoliniumenhancing lesions in treated subjects. Although these preliminary data are encouraging, these reports need to be interpreted cautiously. The small number of patients treated in this trial was selected on the basis of having comparably active brain MRIs at the time of enrollment, so that the observed decreased inflammatory activity under statin treatment may reflect the regression to the mean. To address this issue, a larger, 152-patient, placebo-controlled trial (see http://immunetolerance.org/staycis/) is currently being conducted, and the results are eagerly being awaited. In this trial, patients who have experienced a first CNS demyelinating attack (i.e., a "clinically isolated syndrome") are treated for 12 months with 80 mg atorvastatin in 14 centers in North America. The primary endpoint of this study is met either by a further clinical exacerbation resulting in clinically definite relapsing-remitting MS, or more than three new T2 or gadolinium-enhancing MRI brain lesions. A clinical trial testing atorvastatin for the treatment of rheumatoid arthritis obtained encouraging data for this Th1-mediated organ-specific autoimmune disease. 45 In addition to their ongoing disease-modifying anti-rheumatic drug therapy, rheumatoid arthritis patients were treated with 40 mg atorvastatin or placebo daily. Compared with the active placebo arm, atorvastatin treatment mediated clinical improvement that was associated with a decreased level of inflammation markers.
Current trials may determine that oral statins are only partially effective as monotherapy in the treatment of MS. If so, they might prove to be useful in combination with existing parenteral disease-modifying medications. For instance, GA is a well-tolerated polypeptide-based therapy approved for relapsing-remitting MS that appears to preferentially cause a Th2 deviation of myelinspecific T cells. 46, 47 Furthermore, more recent data indicate that GA treatment mediates immunomodulatory activity on APC, promoting the secretion of anti-inflammatory cytokines and inhibiting the secretion of proinflammatory cytokines. 48, 49 In EAE, the combination of GA and atorvastatin synergistically ameliorated established paralysis, 15 which was associated with an enhanced differentiation of T cells into anti-inflammatory Th2 cells. In vitro experiments revealed that this combination also altered the cytokine profile of activated monocytes in an additive manner. Based primarily on these findings, clinical trials testing atorvastatin in combination with GA are being anticipated. Encouraging results were also obtained from testing the combination of atorvastatin and 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside, an immunomodulating agent that activates AMP-activated protein kinase. 50 This combination was an additive for EAE prevention and reduced cellular infiltration of the CNS more than either drug alone. In addition, this combination lessened axonal loss, which might be of particular interest for treatment of MS at the later neurodegenerative stage. A recent study suggests that the combination of atorvastatin and high-dose interferon beta 1a (Rebif Serono, Geneva, Switzerland), another approved drug for MS treatment, may however not be of clinical benefit. Patients administering interferon beta 1a for at least 6 months were randomized in a double-blind fashion to one of three groups: 1) daily placebo, 2) daily medium dose atorvastatin (40 mg per day), or 3) daily high-dose atorvastatin (80 mg per day) as add on therapy. When the clinical and imaging data for this trial were combined, the analysis indicated that this combination may be antagonistic and lead to paradoxically increased MS activity. 51 However, these data must be viewed cautiously as they were obtained from a small single-center study. A multicenter, rater-blinded, parallel group study is currently testing the combination of 40 mg of atorvastatin and interferon beta 1b in 80 relapsing-remitting MS patients. Results from this study and further studies that are continuing to treat MS patients with the combination of statins and interferon-beta are anticipated.
Statins in treatment of other neurological disorders
Independent of their effect on immune cells, statins may directly have neuroprotective effects on neuronal and glial cells that may extend their applicability to treatment of noninflammatory neurological conditions. In vitro, statins protect neurons from excitotoxic death caused by brain ischemia. 52 As this neuroprotective effect was substantially attenuated by co-treatment with either mevalonate or cholesterol, it may be directly related to statin-mediated inhibition of neuronal cholesterol biosynthesis. Furthermore, lovastatin inhibited degeneration of oligodendrocyte progenitors, 53 a process that is believed to contribute to impaired remyelination after myelin sheath damage. Indeed, lovastatin treatment restored remyelination in the spinal cord of mice with EAE, which was associated with increased expression of myelin proteins and transcription factors involved in differentiating oligodendrocytes. 53 Furthermore, statin use might reduce prevalence or severity of Alzheimer's disease (AD). 54, 55 In a small proof-of-concept study, patients with mild to moderate AD received 80 mg atorvastatin daily for 1 year and improved significantly on the AD Assessment Scale. 56 Various statin-mediated effects might account for this clinical benefit. In an animal model of AD, cholesterol was found to facilitate the production of amyloid ␤, the putative neurotoxic precipitate in AD. 57, 58 In another model, in vivo treatment with simvastatin reduced cholesterol and the production of amyloid ␤. Taken together, these data indicate that statins might inhibit accumulation of amyloid ␤ in CNS plaques by inhibition of cholesterol biosynthesis. Although AD is a neurodegenerative disease, there is evidence that inflammation might contribute to its pathogenesis. 59 In addition, statins might prove to be beneficial in the treatment of AD, owing to their newly discovered anti-inflammatory properties.
There is also strong evidence that several properties of statins may contribute to preventing an ischemic stroke. As previously described, statins reduce the secretion of proteolytic MMPs, lower expression of endothelial adhesion molecules, and inhibit activation of immune cells, factors which may facilitate the rupture of an existing atherosclerotic plaque, 60 resulting in an atherogenic thrombus. Statins enhance endothelial NOS, leading to relaxation of the vascular bed, reduced proliferation of vascular smooth muscle, and inhibition of thrombocyte aggregation. 61 Statins appear to directly deactivate platelets, which may further reduce the risk for a thrombus. 62 In experimental CNS ischemia, immediately initiated statin treatment resulted in an improved clinical outcome. 63 In patients with known ischemic heart disease, statins prevented the occurrence of a secondary ischemic stroke by 21%. 64 In individuals with high-risk factors to developing a stroke, such as hypertension or diabetes, statin treatment also reduced the incidence of a first stroke. 65 To determine whether statins can prevent a stroke in patients without any of these predispositions, a large clinical trial with 4700 patients randomized to either 80 mg atorvastatin or a placebo is currently underway. 66 
Adverse effects of statins
Although generally considered safe and well-tolerated drugs, statins do have side effects. Statins are metabolized by the cytochrome P450 pathway, thereby occasionally causing hepatotoxicity (Ͻ3% of patients), predominantly with a reversible elevation of transaminases. This side effect should be particularly considered when statins are administered in combination with other agents metabolized through the cytochrome P450 pathway. Myopathy is a rare (less than 0.2 %), [67] [68] [69] but potentially severe adverse event, as it can lead to rhabdomyolysis (less than 0.05 %) and even kidney failure. 70 Again, rhabdomyolysis is more likely to occur when statins are used with other drugs, especially lipid-lowering fibrates, and with compounds that are similarly metabolized by the cytochrome P450 pathway. Another side effect occasionally reported in association with statin treatment is idiopathic polyneuropathy. However, a comparative study revealed that the relative risk for a polyneuropathy to occur under statin treatment was only slightly higher than in the hyperlipidemia nontreated cohort or the general population.
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CONCLUSIONS
Besides their lipid-lowering properties, statins exert pleiotropic immunomodulatory effects that may be of therapeutic benefit in CNS autoimmune disease. In murine EAE, statins have shown to target multiple key elements of the immunologic cascade that is believed to lead to inflammatory infiltration and tissue damage in MS. Recent data indicate that statins mediate the majority of their anti-inflammatory properties through inhibition of an alternative branch of the mevalonate pathway, which is primarily recognized for its product, cholesterol. To date, two small open-label trials have tested oral statin treatment in relapsing-remitting MS and reported encouraging preliminary results. Based on these findings, the outcome of a larger placebo-controlled trial testing atorvastatin in early MS is being awaited with high expectations.
